Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

<b>Background/Objectives</b>: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify fa...

全面介紹

書目詳細資料

發表在:	Neurology International
Main Authors:	Takafumi Tanei, Shun Yamamoto, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Yoshiki Ito, Miki Hashida, Takahiro Suzuki, Hajime Hamasaki, Toshihiko Wakabayashi, Ryuta Saito
格式:	Article
語言:	英语
出版:	MDPI AG 2025-04-01
主題:	lasmiditan migraine 50 mg
在線閱讀:	https://www.mdpi.com/2035-8377/17/5/62